Compare · ORKA vs QTNT
ORKA vs QTNT
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and Quotient Limited (QTNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and QTNT operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $3.86B, about 24.7x QTNT ($156.5M).
- ORKA has hit the wire 11 times in the past 4 weeks while QTNT has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 2 for QTNT).
- Company
- Oruka Therapeutics Inc.
- Quotient Limited
- Price
- $64.03+6.51%
- $0.40+10.10%
- Market cap
- $3.86B
- $156.5M
- 1M return
- +0.02%
- -
- 1Y return
- +409.39%
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 11
- 0
- Recent ratings
- 11
- 2
Quotient Limited
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ COVID-19 Microarray that is designed as a serological disease screening microarray specific to COVID-19 antibody detection. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
Latest ORKA
- Oruka Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Dambkowski Carl
- SEC Form 4 filed by Director Kulkarni Samarth
- SEC Form 4 filed by Director Martin Christopher Nathan
- SEC Form 4 filed by Director Ball Kristine M
- SEC Form 4 filed by Director Fairmount Funds Management Llc
- Oruka Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
- Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- Director Dambkowski Carl exercised 62,260 shares at a strike of $7.95 and sold $6,191,366 worth of shares (105,000 units at $58.97) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 73,743 units (SEC Form 4)
Latest QTNT
- SEC Form 15-12G filed by Quotient Limited
- SEC Form EFFECT filed by Quotient Limited
- SEC Form EFFECT filed by Quotient Limited
- SEC Form EFFECT filed by Quotient Limited
- SEC Form EFFECT filed by Quotient Limited
- SEC Form EFFECT filed by Quotient Limited
- SEC Form EFFECT filed by Quotient Limited
- SEC Form EFFECT filed by Quotient Limited
- SEC Form EFFECT filed by Quotient Limited
- SEC Form POS AM filed by Quotient Limited